MSB 2022 - The road to commercialisation, page-1491

@ddwn

Mate, if I could get to the meeting and speak with anyone in management, I would press upon them the need to keep shareholders better informed.

Whether about partnerships or the fda process, clearly there's been endless unexpected hurdles.
As shareholders we can accept that, we understand it's a very complex process.
But to continually inform shareholders the absolute bare minimum and at times even disguise the information as to make things unclear - it really reflects badly on management and the credibility of the co.

1. Tell us when you reach a hurdle.
2. Tell us how you plan to deal with it.
3. Give us a clear timeline.
4. Update us when the timeline is not going to be met.

I believe in science, but I'm really losing faith in management.